MediGene receives further European patent on EndoTAG-1
German biotech company MediGene has obtained an extended patent from the European Patent Office on the manufacturing process for the drug candidate EndoTAG-1.
German biotech company MediGene has obtained an extended patent from the European Patent Office on the manufacturing process for the drug candidate EndoTAG-1.
The patent protects the manufacturing process used for the candidate, including the drying step applied, products manufactured by the specified steps, products with identical properties, as well as further specified dried cationic liposomal compounds. The term of the patent ends in 2023.
Dr Frank Mathias, MediGene's chief executive, said: "This new patent is extremely important for MediGene and for the commercialisation of EndoTAG-1. In addition to the patent protection that we already possess for the EndoTAG technology in general and for EndoTAG-1 in particular, the manufacturing process and the dried formulation of our drug candidate are now also patented."
Overall patent protection has been renewed for the product and the protected territory has been enlarged by a number of European countries.
Although EndoTAG-1 is administered in the form of a suspension, the drug will be commercialised as a dried product.
EndoTAG-1 selectively attacks blood vessels needed for the growth of tumours. It is a combination of positively charged liposomes and the embedded active substance paclitaxel.
The drug candidate has obtained orphan drug designation for Europe and the US.